Llwytho...
The role of B cells in multiple sclerosis: current and future therapies
While it was long held that T cells were the primary mediators of multiple sclerosis (MS) pathogenesis, the beneficial effects observed in response to treatment with Rituximab, a monoclonal antibody (mAb) targeting CD20, shed light on a key contributor to MS that had been previously underappreciated...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cell Immunol |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6540809/ https://ncbi.nlm.nih.gov/pubmed/31130183 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cellimm.2018.10.006 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|